After three years of follow up, the data suggests that levels of cancer relapse did not increase in people with high-risk, advanced stage melanoma.After three years of follow up, the data suggests that levels of cancer relapse did not increase in people with high-risk, advanced stage melanoma.
Patients in the phase 2b trial had high-risk melanomas and either had the jab, developed by Moderna and Merck, alongside the immunotherapy Keytruda or were given only Keytruda. Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the results marked another milestone in “the exciting, developing landscape of cancer vaccine research”.
A sample of tumour is removed during the patient’s surgery, followed by DNA sequencing and the use of artificial intelligence. The result is a custom-built anti-cancer jab specific to the patient’s tumour.